Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons

References

• Centers for Disease Control and Prevention. HIV/AIDS. Available at: http://www.cdc.gov/hiv/statistics/basics/ataglance.html [Last accessed February 2015]
   Google Scholar
• Solem CT, Snedecor SJ, Khachatryan A, et al. Cost of treatment in a US commercially insured, HIV-1-infected population. PLoS One 2014;9:e98152
   PubMed Web of Science ®Google Scholar
• Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA Panel. JAMA 2014;312:410-25
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60
   PubMed Web of Science ®Google Scholar
• Potard V, Chassany O, Lavignon M, et al. Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. AIDS Care 2010;22:54-61
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013;27:973-9
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30
   PubMed Web of Science ®Google Scholar
• Clucas C, Harding R, Lampe FC, et al. Doctor–patient concordance during HIV treatment switching decision-making. HIV Med 2011;12:87-96
   PubMed Web of Science ®Google Scholar
• Battaglioli-DeNero AM. Strategies for improving patient adherence to therapy and long-term patient outcomes. J Assoc Nurses AIDS Care 2007;18:S17-S22
   PubMed Web of Science ®Google Scholar
• Schaecher KL. The importance of treatment adherence in HIV. Am J Manag Care 2013;19:S231-S7
   PubMed Web of Science ®Google Scholar
• Al-Dakkak I, Patel S, McCann E, et al. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care 2013;25:400-14
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hsu AJ, Uthman OA, et al. Antiretroviral therapy adherence and drug–drug interactions in the aging HIV population. AIDS 2012;26:S39-S53
   PubMedGoogle Scholar
• Bernardini C, Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Patient Prefer Adherence 2013;7:531-42
   PubMed Web of Science ®Google Scholar
• Pádua CA, César CC, Bonolo PF, et al. Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil. Braz J Infect Dis 2007;11:20-6
   PubMed Web of Science ®Google Scholar
• Nagpal M, Tayal V, Kumar S, Gupta U. Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: a prospective observational study. Indian J Med Sci 2010;64:245-52
   PubMedGoogle Scholar
• Chen WT, Shiu CS, Yang JP, et al. Antiretroviral therapy (ART) side effect impacted on quality of life, and depressive symptomatology: a mixed-method study. J AIDS Clin Res 2013;4:218
   PubMedGoogle Scholar
• Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs 2013;73:651-72
   PubMed Web of Science ®Google Scholar
• Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013;207:1359-69
   PubMed Web of Science ®Google Scholar
• Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis 2000;30:908-14
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Lundgren JD, Roediger MP, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011;25:367-77
   PubMed Web of Science ®Google Scholar
• Tripathi A, Jerrell JM, Liese AD, et al. Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994–2011. Metab Syndr Relat Disord 2013;11:417-26
   PubMed Web of Science ®Google Scholar
• Wallace BJ, Tan KB, Pett SL, et al. Enfuvirtide injection site reactions: a clinical and histopathological appraisal. Australas J Dermatol 2011;52:19-26
   PubMed Web of Science ®Google Scholar
• Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014;28:131-45
   PubMed Web of Science ®Google Scholar
• Tadesse WT, Mekonnen AB, Tesfaye WH, Tadesse YT. Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. BMC Pharmacol Toxicol 2014;15:32
   PubMed Web of Science ®Google Scholar
• Boulet T, Pavie J, Charreau I, et al. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin Trials 2010;11:283-93
   PubMed Web of Science ®Google Scholar
• Streinu-Cercel A, de Gorgolas M, Müller M, et al. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study. HIV Clin Trials 2008;9:375-86
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis 2014;46:34-45
   PubMed Web of Science ®Google Scholar
• Masiá M, Martínez E, Padilla S, et al. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. J Antimicrob Chemother 2013;68:409-13
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Colafigli M, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 2013;68:1364-72
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010;4:115-25
   PubMed Web of Science ®Google Scholar
• Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991;29:786-98
   PubMed Web of Science ®Google Scholar
• Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997;6:481-93
   PubMed Web of Science ®Google Scholar
• Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998;36:126-37
   PubMed Web of Science ®Google Scholar
• Johns Hopkins Bloomberg School of Public Health. The Development of the MOS-HIV Questionnaire. Available at: http://www.jhsph.edu/research/affiliated-programs/medical-outcomes-study-HIV/MOS_HIV_Quest/index.html [Last accessed November 2011]
   Google Scholar
• Lovibond SH, Lovibond OH. Manual for the Depression Anxiety Stress Scales (DASS). Psychology Foundation Monograph. Sydney, Australia: University of New South Wales, 1993
   Google Scholar
• The University of New South Wales School of Psychology. Overview of the DASS and its uses. Available at: http://www2.psy.unsw.edu.au/groups/dass//over.htm [Last accessed November 2011]
   Google Scholar
• Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001;10:517-31
   PubMed Web of Science ®Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioural Sciences, 2nd edn. Hillsdale, NJ, USA: Erlbaum, 1988
   Google Scholar